Odyssey Therapeutics Will Present OD-001 Data in October

The Boston-based biotech company plans to share Phase 2a results for its ulcerative colitis drug during UEG Week.

Updated on Oct. 6, 2026 in Biotech

Bold flat-color editorial illustration showing a single glass vial, representing the clinical and institutional focus of the medical data disclosure. — Odyssey Therapeutics will present Phase 2a clinical data for its experimental ulcerative colitis drug, OD-001, on October 20 at the UEG Week forum in Barcelona. AI Illustration. Upload story photo >

Live Poll

Should pharmaceutical companies be required to publicly webcast all major clinical trial data presentations?

Odyssey Therapeutics will present clinical data for its experimental ulcerative colitis drug, OD-001, at the UEG Forum on October 20, 2026. This presentation is part of the broader UEG Week 2026 conference occurring in Barcelona.

Why it matters

The upcoming oral presentation provides a public update on the safety and efficacy of OD-001, a key asset in the pipeline of the clinical-stage biopharmaceutical firm. This data release allows clinicians and investors to evaluate the drug's performance in patients with moderately to severely active ulcerative colitis.

The clinical trial for OD-001 is registered under identifier NCT06850727. The drug is currently being tested in patients diagnosed with moderately to severely active ulcerative colitis.

The players

Odyssey Therapeutics

This Boston-based, clinical-stage biopharmaceutical company was founded in 2021.

Bruce Sands

He is the designated presenter for the Phase 2a clinical data regarding OD-001.

The details

The oral presentation, titled Safety and Efficacy of OD-001 in Patients with Moderately to Severely Active Ulcerative Colitis, will be delivered by Bruce Sands. Odyssey Therapeutics intends to support this disclosure with a conference call and live webcast for stakeholders.

Odyssey Therapeutics was founded in 2021.
UEG Week 2026 will be held from October 17-20, 2026.
The oral presentation is scheduled for October 20, 2026, at 9:00 a.m. CEST.
The company will host a conference call and webcast on October 20, 2026, at 8:00 a.m. EDT.

The Tech Race

The debut of Phase 2a data at the UEG Forum follows the industry trend of leveraging major scientific conferences to validate novel therapeutic platforms. This release marks a significant milestone for Odyssey Therapeutics as it competes within the crowded biopharmaceutical landscape.

Stakeholders and investors can access the upcoming presentation and subsequent conference call directly through the company's official website. A replay of the discussion will remain available for public viewing for 180 days following the event.

The takeaway

This event serves as a major touchpoint for stakeholders monitoring the progress of emerging treatments for inflammatory bowel diseases. Investors and observers should track the upcoming webcast to understand the potential clinical trajectory of the company's pipeline.

What happens next

Odyssey Therapeutics will host a conference call and webcast on October 20, 2026, at 8:00 a.m. EDT to discuss the trial findings, with a replay archived on their website for 180 days.